Letter

Fetal RHD typing

Is fetal RHD typing in all RhD negative women cost effective?

BMJ 2008; 336 doi: 10.1136/bmj.39556.499549.80 (Published 24 April 2008)
Cite this as: BMJ 2008;336:906.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ala Szczepura, professor, health services research1,
  2. Gouke Bonsel, professor, evaluation of health care2,
  3. Christian Krauth, associate professor, health economics and public health 3,
  4. Leeza Osipenko, senior research fellow1,
  5. Alexander Haverkamp, research fellow4
  1. 1Clinical Sciences Institute, Warwick Medical School, University of Warwick
  2. 2Institute for Health Management and Policy, Department of Prenatal and Reproductive Care, Erasmus Medical Centre, Rotterdam University, Netherlands
  3. 3Institute for Epidemiology, Social Medicine and Health System Research, Hanover Medical School, Germany
  4. 4Department of Transfusion Medicine, Georg-August-University, Göttingen, Germany
  1. ala.szczepura{at}warwick.ac.uk

    Finning et al show that non-invasive detection of fetal RHD status can be performed in a high throughput laboratory with high sensitivity.1 The associated editorial suggests that universal fetal genotyping of all RhD negative women is a logical extension that would allow the targeting of antenatal anti-D prophylaxis. But would mass testing be cost effective and, if so, under what conditions? The original …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular